Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Endoxifen (z-endoxifen) is the most active metabolite of the FDA approved selective estrogen receptor modulator (SERM), tamoxifen. It has demonstrated that the anti-estrogenic effects and is being evaluated for ER+/HER2+ breast cancer.
Lead Product(s): Endoxifen
Therapeutic Area: Oncology Product Name: Endoxifen
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Quantum Leap Healthcare
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2023
Details:
Endoxifen (z-endoxifen) is the most active metabolite of the FDA approved selective estrogen receptor modulator (SERM), tamoxifen. It has demonstrated that the anti-estrogenic effects and is being evaluated for ER+/HER2+ breast cancer.
Lead Product(s): Endoxifen
Therapeutic Area: Oncology Product Name: Endoxifen
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2023
Details:
Under the agreement, Societal CDMO will provide a range of its Clinical Trial Services offerings focused on Atossa’s proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, the most active metabolite of the FDA approved SERM, tamoxifen.
Lead Product(s): Endoxifen
Therapeutic Area: Oncology Product Name: Endoxifen
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Societal CDMO
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 23, 2023
Details:
(Z)-endoxifen is the most active metabolite of the FDA approved selective estrogen receptor modulator (SERM), tamoxifen. It has demonstrated that the anti-estrogenic effects and is being evaluated for ER+/HER2+ breast cancer.
Lead Product(s): Endoxifen
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Quantum Leap Healthcare
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2023
Details:
Endoxifen, an active metabolite of tamoxifen, which is an FDA-approved drug to treat ovarian and breast cancer. Endoxifen administered to breast cancer patients prior to surgery.
Lead Product(s): Endoxifen
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2021
Details:
The positive assessment by the safety committee allows the study to now enroll the next cohort, which will be the third of a total of four cohorts and the first of two multi-dose, placebo controlled cohorts evaluating AT-301A over AT-301B.
Lead Product(s): AT-301
Therapeutic Area: Infections and Infectious Diseases Product Name: AT-301
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 17, 2020
Details:
The Phase 1 study is a double-blinded, randomized, and placebo-controlled safety study of AT-301 nasal spray in 32 healthy adult subjects divided into two study groups.
Lead Product(s): AT-301
Therapeutic Area: Infections and Infectious Diseases Product Name: AT-301
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 01, 2020
Details:
Atossa has enrolled and first dose of AT-301 in Phase 1 being administered by nasal spray. This group of 8 participants received a single dose of either AT-301A (placebo) or AT-301B (active).
Lead Product(s): AT-301
Therapeutic Area: Infections and Infectious Diseases Product Name: AT-301
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 17, 2020
Details:
The study results show that treatment with Atossa’s proprietary Endoxifen for 20 days prior to unilateral mastectomy and for 18 months after surgery as an adjuvant did not lead to vasomotor symptoms commonly associated with tamoxifen.
Lead Product(s): Endoxifen
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 30, 2020
Details:
The study is a double-blinded, randomized, and placebo-controlled safety study of AT-301 nasal spray in 32 healthy adult subjects divided into two study groups.
Lead Product(s): AT-301
Therapeutic Area: Infections and Infectious Diseases Product Name: AT-301
Highest Development Status: PreclinicalProduct Type: Undisclosed
Recipient: Avance Clinical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 22, 2020